Intent to Apply (ITA)
A total of 17 eligible ITA forms were received. A breakdown of eligible ITA forms by disease, intervention and development stage is shown below:

- **Disease**
  - Malaria, 7
  - Tuberculosis, 4
  - Leishmaniasis, 6
  - Soil-transmitted helminthiasis, 1
  - Echinococcosis, 2
  - Cryptosporidium, 1
  - Schistosomiasis, 1

- **Intervention**
  - Diagnostics, 7
  - Drug, 5
  - Vaccine, 6

- **Development Stage**
  - Pre-clinical, 14
  - Clinical, 4
  - Licensure, 1

*One or more ITA forms included multiple diseases, interventions and/or development stages in the scope.*
Full Proposal
A total of 11 eligible proposals were received. A breakdown of eligible proposals by disease, intervention and development stage is shown below:

### Disease

- Malaria: 3
- Tuberculosis: 3
- Leishmaniasis: 4
- Soil-transmitted helminthiasis: 1

### Intervention

- Drug: 3
- Vaccine: 3
- Diagnostics: 5

### Development Stage

- Pre-clinical: 9
- Clinical: 3

*One or more proposals included multiple diseases, interventions and/or development stages in the scope.*
**Award Notification**

The following five projects were awarded funding.

<table>
<thead>
<tr>
<th>Project Title</th>
<th>Collaboration Partners</th>
<th>Disease</th>
<th>Intervention</th>
<th>Development Stage</th>
<th>Total Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Highly Sensitive POC TB-LAM Rapid Diagnostic Test</strong></td>
<td>1. Foundation for Innovative New Diagnostics (FIND) 2. Fujifilm Corporation</td>
<td>Tuberculosis</td>
<td>Diagnostics</td>
<td>Clinical</td>
<td>¥216,057,769</td>
</tr>
<tr>
<td><strong>Cry5B consortium for soil-transmitted helminths</strong></td>
<td>1. PATH 2. Meiji Seika Pharma CO., LTD. 3. Ajinomoto Co., Inc. 4. University of Massachusetts, Amherst</td>
<td>Soil-transmitted helminthias</td>
<td>Drug</td>
<td>Pre-Clinical</td>
<td>¥100,299,625</td>
</tr>
<tr>
<td><strong>Lead optimization of an evolution-proof malaria transmission-blocking vaccine immunogen that is based on a mosquito protein target and effective against both P. falciparum and P. vivax</strong></td>
<td>1. University of Florida 2. CellFree Sciences Co., Ltd. (CFS)</td>
<td>Malaria</td>
<td>Vaccine</td>
<td>Pre-Clinical</td>
<td>¥41,928,575</td>
</tr>
</tbody>
</table>